- ISIN
- US58506Q1094
- CUSIP
- 58506Q109
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- IPO Date
- Aug 11, 2016
Highlights
- Market Cap
- $13.71B
- Enterprise Value
- $13.18B
- EPS (TTM)
- $15.63
- PE Ratio
- 30.29
- PEG Ratio
- 0.91
- Total Revenue (TTM)
- $2.68B
- Gross Profit (TTM)
- $778.59M
- EBITDA (TTM)
- $572.96M
- Year Range
- $305.69 - $628.92
- Target Price
- $534.17
- ROA (TTM)
- 21.62%
- ROE (TTM)
- 76.95%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
MEDP Performance Chart
Medpace Holdings, Inc. (MEDP) is down 15.7% since the beginning of the year. At $473 per share, MEDP is trading 24.7% below its 52-week high of $629. Investors who bought $1,000 worth of MEDP shares 5 years ago would now be looking at an investment worth $2,661.
Loading charts...
Returns By Period
Medpace Holdings, Inc. (MEDP) has returned -15.70% so far this year and 53.41% over the past 12 months.
Medpace Holdings, Inc.
- 1D
- 3.91%
- 1M
- 9.40%
- YTD
- -15.70%
- 6M
- -16.89%
- 1Y
- 53.41%
- 3Y*
- 28.45%
- 5Y*
- 21.62%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
MEDP Monthly Returns History
Based on dividend-adjusted daily data since Aug 11, 2016, MEDP's average daily return is +0.16%, while the average monthly return is +3.09%. At this rate, an investment would double in approximately 1.9 years.
Historically, 63% of months were positive and 37% were negative. The best month was Jul 2018 with a return of +42.7%, while the worst month was Feb 2026 at -22.4%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.
On a daily basis, MEDP closed higher 54% of trading days. The best single day was Jul 22, 2025 with a return of +54.7%, while the worst single day was May 2, 2017 at -30.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.71% | -22.44% | 6.29% | -12.81% | 6.80% | 5.90% | -15.70% | ||||||
| 2025 | 5.09% | -6.25% | -6.91% | 1.21% | -4.37% | 6.43% | 36.11% | 11.31% | 8.13% | 13.76% | 1.29% | -5.20% | 69.05% |
| 2024 | -4.88% | 36.33% | 1.67% | -3.91% | -0.52% | 6.60% | -7.12% | -7.12% | -6.04% | -5.87% | 8.40% | -2.47% | 8.38% |
| 2023 | 4.08% | -12.30% | -3.01% | 6.43% | 3.41% | 16.04% | 5.41% | 6.75% | -10.41% | 0.22% | 11.56% | 13.23% | 44.31% |
| 2022 | -18.46% | -13.80% | 6.94% | -18.35% | 7.24% | 4.49% | 13.27% | -12.93% | 6.48% | 41.24% | -5.45% | 1.20% | -2.40% |
| 2021 | -4.60% | 22.32% | 1.00% | 3.43% | -1.54% | 5.73% | -0.39% | 3.64% | 3.80% | 19.69% | -8.45% | 4.93% | 56.35% |
Benchmark Metrics
Medpace Holdings, Inc. has an annualized alpha of 26.81%, beta of 1.21, and R2 of 0.20 versus S&P 500 Index. Calculated based on daily prices since August 11, 2016.
- This stock captured 199.86% of S&P 500 Index gains and 116.39% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.20 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 26.81%
- Beta
- 1.21
- R²
- 0.20
- Upside Capture
- 199.86%
- Downside Capture
- 116.39%
Return for Risk
Risk / Return Rank
MEDP ranks 72 for risk / return — better than 72% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Medpace Holdings, Inc. (MEDP) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MEDP | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.00 | ||
| Sortino ratioReturn per unit of downside risk | -0.60 | ||
| Omega ratioGain probability vs. loss probability | 1.31 | 1.32 | -0.01 |
| Calmar ratioReturn relative to maximum drawdown | 1.47 | 2.46 | -0.99 |
| Martin ratioReturn relative to average drawdown | 3.17 | 10.92 | -7.75 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Medpace Holdings, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Medpace Holdings, Inc. was 42.87%, occurring on Apr 27, 2022. Recovery took 180 trading sessions.
The current Medpace Holdings, Inc. drawdown is 23.70%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -42.87%Apr 2022 | 4mo | 8mo 21d | 1y 16dDec 2021 - Jan 2023 |
2017 bear market2017 | -41.43%May 2017 | 4mo 27d | 7mo 20d | 1y 12dDec 2016 - Dec 2017 |
COVID crash2020 | -39.47%Mar 2020 | 21d | 3mo 29d | 4mo 20dFeb 2020 - Jul 2020 |
2025 selloff2025 | -39.38%Apr 2025 | 8mo 25d | 3mo 15d | 1y 5dJul 2024 - Jul 2025 |
2026 bear market2026 | -36.61%Apr 2026 | 3mo 1d | — | 5mo 3dJan 2026 - now |
Drawdown Indicators
| MEDP | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -42.87% | -56.78% | +13.91% |
Max Drawdown (1Y)Largest decline over 1 year | -36.61% | -9.10% | -27.51% |
Max Drawdown (3Y)Largest decline over 3 years | -39.38% | -18.90% | -20.48% |
Max Drawdown (5Y)Largest decline over 5 years | -42.87% | -25.43% | -17.44% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -23.70% | -3.21% | -20.49% |
Average DrawdownAverage peak-to-trough decline | -12.95% | -10.71% | -2.24% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 16.91% | 2.04% | +14.87% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Medpace Holdings, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Medpace Holdings, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for MEDP, comparing it with other companies in the Diagnostics & Research industry. Currently, MEDP has a P/E ratio of 30.3. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for MEDP compared to other companies in the Diagnostics & Research industry. MEDP currently has a PEG ratio of 0.9. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for MEDP relative to other companies in the Diagnostics & Research industry. Currently, MEDP has a P/S ratio of 5.2. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for MEDP in comparison with other companies in the Diagnostics & Research industry. Currently, MEDP has a P/B value of 22.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with MEDP
Add Medpace Holdings, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with MEDP